OCUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ocular Therapeutix Inc (OCUL) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The stock has strong analyst support with significant upside potential, positive catalysts from clinical trial results, and hedge fund buying activity. Despite short-term technical and financial challenges, the long-term growth potential in the wet AMD market makes it an attractive investment.
The MACD is positive and contracting, indicating a potential upward momentum. RSI is neutral at 57.161, showing no overbought or oversold conditions. The stock is trading near its pivot level of 8.685, with support at 8.118 and resistance at 9.252. Pre-market price is down 2.14%, but this could be a temporary dip.
Analysts have raised price targets significantly, with targets ranging from $27 to $34, citing strong Phase 3 trial results and potential approval for Axpaxli.
Hedge funds are heavily buying, with a 2312.47% increase in buying activity last quarter.
Positive sentiment from recent news, including Axpaxli's favorable safety profile and upcoming conferences.
Insiders are selling, with a 186.05% increase in selling activity last month.
Financial performance shows declining revenue (-22.43% YoY) and negative net income, though losses have narrowed.
Short-term stock trend analysis indicates a 40% chance of a slight decline in the next day and week.
In 2025/Q4, revenue dropped by 22.43% YoY to $13.25M, while net income improved to -$64.65M, up 33.62% YoY. EPS remained flat at -0.29, and gross margin decreased by 5.20% YoY to 87.97%. The company is still in a growth phase, with financials reflecting high R&D expenses for drug development.
Analysts are overwhelmingly positive on OCUL, with multiple Buy ratings and price targets raised to $27-$34. Analysts cite strong Phase 3 trial data for Axpaxli, which addresses a significant unmet need in the $14B wet AMD market, as a key driver for long-term growth.
